EASD 2021 Cardiac adipose tissue measured by CT was reduced by treatment with liraglutide compared to placebo in patients with T2DM, but this reduction was dependent on changes in weight loss.

EASD 2021 This secondary analysis of the DAPA-CKD trial showed that the efficacy and safety of dapagliflozin on kidney and CV outcomes was consistent across subgroups of baseline albuminuria in patients with CKD, with and without T2DM.

EASD 2021 There is a wide distribution of 10-year and lifetime CV risk in diabetes patients with and without a history of CVD. Use of SGLT2 inhibitors and GLP-1RAs was low in all groups.

EASD 2021 This analysis showed that semaglutide reduced the risk of MACE compared to placebo regardless of metformin use in patients with T2DM.

EASD 2021 In patients with diabetes, included in the Hoorn Diabetes Care System cohort, measures of kidney disease, eGFR and UACR, were differentially associated with subtypes of CVD.

EASD 2021 This analysis showed that improvements in two or more risk markers were associated with reduced risk of expanded MACE, CV death and nephropathy in patients with T2DM.

ESC 2021 FIDELITY was a prespecified pooled analysis of FIDELIO-DKD and FIGARO-DKD, which showed that finerenone reduced the risk of CV and renal outcomes in patients with T2DM and mild-to-severe CKD.

ESC 2021 Kevin Damman discusses the results of the FIGARO-DKD trial which compared the nonsteroidal MRA finerenone with placebo in patients with diabetes and chronic kidney disease.

ESC 2021 The FIGARO-DKD trial showed that the nonsteroidal MRA finerenone significantly reduced the risk of CV outcomes in patients with mild-to-moderate kidney disease and diabetes.

This study showed that individuals with metabolically healthy obesity were at higher risk of diabetes, ASCVD, HF, respiratory diseases and all-cause mortality, compared with people with metabolically healthy non-obesity.

This study showed that estimated age-standardized prevalence of diabetes among US adults increased significantly from 9.8% in 1999-2000 to 14.3% in 2017-2018. In 2015-2018, only 21.2% of adults with diagnosed diabetes achieved individualized HbA1C targets, BP <130/80 mmHg, and LDL-c <100 mg/dL.

Microvascular disease (MVD) was associated with the development of HF in adults with T2DM, independently of traditional risk factors including CAD.